A Watch Out on Active Scrips from Diverse Sectors – Research on Innodata, Oxysure Systems, CytoDyn and Roadships Holdings

NEW YORK, NY / ACCESSWIRE / November 2, 2015 / Moments ago, Trader’s Choice released new research updates concerning several important developing situations including the following equities: Innodata Inc. (NASDAQ: INOD), Oxysure Systems Inc. (OTC: OXYS), CytoDyn Inc. (OTC: CYDY) and Roadships Holdings Inc. (OTC: RDSH). Trader’s Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full research reports are being made available to the public on a complimentary basis.

To access our full PDF reports for free, please visit the links below.

============

Full PDF DOWNLOAD Links

(You may have to copy and paste the links into your browser)

INOD Research Report: http://www.traders-choice.com/pdf?s=INOD

OXYS Research Report: http://www.traders-choice.com/pdf?s=OXYS

CYDY Research Report: http://www.traders-choice.com/pdf?s=CYDY

RDSH Research Report: http://www.traders-choice.com/pdf?s=RDSH

============

Highlights from today’s reports include:

On Friday, October 30, 2015, the U.S. markets finished marginally lower as the NASDAQ Composite ended at 5,053.75, down 0.40%, the Dow Jones Industrial Average edged 0.52% lower to finish the day at 17,663.54, and the S&P 500 closed at 2,079.36, down 0.48%.

– The stock of Innodata Inc. lost 0.42% to close Friday’s session at USD 2.36. The shares of the company moved in the range of USD 2.36 and USD 2.42. A trading volume of 0.02 million shares was recorded, which was greater than its 150-day daily average volume of 0.01 million shares. Over the last five days Innodata Inc.’s shares have advanced 7.27% and in the past one month the stock has gained a momentum of 1.29%. Additionally, over the last three months the stock has declined 9.92% and in the past six months the shares have registered a loss of 9.58%. The company stock is trading at a price to book ratio of 1.61, while its historical PB ratio is near to 1.89. Further, the stock is trading at a price to cash flow ratio of 57.19 and price to sales ratio of 1.03. Moreover, the company’s debt-to-equity ratio stood at 0.18. In its earnings release on October 29, 2015, the company reported sequential as well as annual increases in total revenue and EPS, which stood at USD 15.13 million and USD 0.02 per diluted share, respectively.

– OxySure Systems Inc.’s stock increased by 0.04% to close Friday’s session at USD 0.26. The company’s shares fluctuated in the range of USD 0.23 and USD 0.26. A total of 0.13 million shares exchanged hands, which was above its 52-week average volume of 0.10 million shares. Over the last three days OxySure Systems Inc.’s shares have advanced 18.18% and in the past one week the stock has moved up 11.73%. Furthermore, over the last three months the stock has lost 39.53% and in the past six months the shares have shed 63.12%. The company stock is trading at a price to book ratio of 2.8 and price to sales ratio of 2.4. The company stock’s 200-day moving average stood at 0.58 with a market capitalization of USD 8.3 million. The company is engaged in the design, manufacture and distribution of specialty respiratory and emergency medical solutions and related medical products and accessories.

– CytoDyn Inc.’s stock slipped by 4.49% to close Friday’s session at USD 0.85. The company’s shares oscillated between USD 0.85 and USD 0.92. The stock recorded a trading volume of 0.11 million shares, which was above its 50-day daily average volume of 0.10 million shares and 52-week average volume of 0.09 million shares. Over the last five days CytoDyn Inc.’s shares have declined by 3.41% while over the last three months the stock has lost 12.37%. However, the shares have shed 26.09% on year to date basis. The company has returned 13.33% in the past one year, on a compounded total return basis. The stock is trading at a market capitalization of USD 71.1 million. In a recent release published on October 22, 2015, the company announced that the first patient in its Phase 3 clinical trial involving 300 HIV patients has been injected with PRO 140, which is the first self-injectable antibody for the treatment of HIV. CytoDyn is a biotechnology company engaged in the clinical development and potential commercialization of humanized monoclonal antibodies to treat HIV infection.

– Roadships Holdings Inc.’s stock declined 8.00% to close Friday’s session at USD 0.02. The share price vacillated between USD 0.02 and USD 0.03. The stock recorded a trading volume of 1.01 million shares, which was below its 50-day daily average volume of 1.18 million shares and 52-week average volume of 4.01 million shares. Over the last three days Roadships Holdings Inc.’s shares have declined by 25.81% and in the past one week the stock has moved down 36.81%. However, in the last one month and six months the stock has gained 132.32% and 1110.53%, respectively, while year to date the shares have picked up 11400.00%. On a compounded total return basis, the company has returned 1252.94% in the last half a year and 7566.67% in the past one year. With a market capitalization of USD 68.7 million, Roadships Holdings is engaged in the short-sea and ground freight transport industry sectors and internet applications industry sector.

About Trader’s Choice:

Trader’s Choice (“TC”) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. TC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TC has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer (collectively referred to as the “Production Team”) in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein. The information in this release has been sourced from a third party data base.

NO WARRANTY

TC, the Author and the Reviewer (collectively referred to as the “Publishers”) are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.traders-choice.com/.

RESTRICTIONS

TC is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

E-mail: press (at) traders-choice.com

SOURCE: Trader’s Choice

ReleaseID: 433150